Building up its rare obesity pipeline, Rhythm Pharma to raise $150M

With fresh data in-hand for a slew of late-stage clinical trials in rare obesity diseases, Rhythm Pharma $RYTM signaled plans today to raise $150 million in a follow-on offering.